Comparison of polyphenol-rich wine grape seed flour-regulated fecal and blood microRNAs in high-fat, high-fructose diet-induced obese mice. (October 2020)

• Record Type: Journal Article
• Authors: Seo, Kun-Ho; Yokoyama, Wallace; Kim, Hyunsook
• Is Part Of: Journal of functional foods. Volume 73(2020)
• Publication Date: 2020-10
• Subjects: miRNA biomarker -- Obesity -- Feces -- Blood -- Polyphenol; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2020.104147
• Languages: English
• ISSNs: 1756-4646

Abstract

Graphical abstract: Highlights: Wine grape seed flour (GSF) inhibited high-fructose high-fat-induced obesity. miRNome analysis found novel miRNAs regulated by GSF. miR-129-5p in both blood and feces was significantly affected by GSF. miR-129-5p had a strong correlation with obesity-related physiological biomarkers. Fecal miR-129-5p is a potential noninvasive biomarker for monitoring GSF efficacy. Abstract: A biomarker, easily and noninvasively measured in feces, can be useful in monitoring efficacy of novel functional foods against complicated pathologies of obesity-related metabolic diseases. Fecal microRNA (miRNA)s were analyzed for potential noninvasive biomarkers in C57BL/6J mice fed a high-fat and high-fructose diet (HFrD) containing either microcrystalline cellulose (MCC) or 5% polyphenol-rich wine grape seed flour (GSF) for 8 weeks. GSF supplementation significantly reduced HFrD-induced body weight gain, visceral adiposity, and hyperlipidemia. miRNome analysis revealed that GSF supplementation significantly ( p < 0.05; fold-change, |FC| ≥ 1.5) regulated 82 and 4 miRNAs in the feces and blood, respectively. Among these miRNAs, 22 in feces and 4 in blood were strongly associated with obesity-related physiological biomarkers, and miR-129-5p in both blood and feces showed a strong correlation with obesity-related biomarkers. These results suggest that fecal miR-129-5p is a potentially useful noninvasive biomarker in monitoring personalized GSF efficacy against obesity and obesity-metabolic disease.